Cardiovascular pharmacogenomics is a cutting-edge field that explores the intersection of genetics and cardiovascular medicine. It focuses on how an individual's genetic makeup influences their response to cardiovascular drugs, aiming to optimize treatment outcomes and minimize adverse effects. By studying the genetic variations that affect drug metabolism, efficacy, and toxicity, researchers in cardiovascular pharmacogenomics seek to tailor medication regimens to each patient's unique genetic profile. This personalized approach holds the potential to enhance the effectiveness of cardiovascular therapies, reduce the likelihood of side effects, and improve overall patient outcomes. As our understanding of the human genome continues to advance, cardiovascular pharmacogenomics promises to play a crucial role in the evolution of precision medicine, bringing us closer to more individualized and targeted treatments for cardiovascular diseases.
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Fats of life, the skinny on novel lipid therapies beyond statins
Ahdy Wadie Helmy, Indiana University School of Medicine, United States
Title : Movement is medicine
Steve Cohen, Medvesta Hypnosis Healthcare, United States
Title : Novel ways of cardiovascular risk assessment
Syed Raza, Awali Hospital, Bahrain
Title : Analysis of cardiovascular risk factors in patients with type 1 diabetes mellitus
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Beyond PCSK9: The next wave of lipid-lowering and thrombosis prevention - from bench to breakthrough
Narendra Kumar, HeartbeatsZ Academy, United Kingdom